Published by Global Banking & Finance Review®
Posted on August 28, 2025
2 min readLast updated: January 22, 2026
Add as preferred source on Google
Ramsay Health Care's profit plummeted due to poor performance in Europe and the UK, leading to a share price drop. Strategic reviews are underway.
(Reuters) -Ramsay Health Care posted a steep drop in its annual results, hurt by a one-off charge and poor performance at its European division and British mental health service business, sending its shares to a more than four-month low.
The Australian private hospital operator posted a net profit after tax of A$24 million ($15.60 million) for the year ended June 30 on Thursday, compared with A$888.7 million a year ago.
That also missed the Visible Alpha consensus estimate of A$70.4 million.
Weaker results from Ramsay Santé, its European arm and Elysium, the British mental health business, higher net financing costs, among others, weighed on the firm's bottom line, the company said.
A one-off post-tax charge of A$291 million related to underperformance at Elysium further squeezed its earnings.
Santé, a private healthcare operator in Europe with its services spread across France, Italy, Norway, among others, has been underperforming for a while now.
Earlier this year, the company hinted at a potential sale of Santé and appointed Goldman Sachs to look at strategic options for its stake in the division.
"Ramsay remains committed to optimising shareholder returns and is reviewing a range of options (for Santé)," the hospital operator said on Thursday.
Shares of the firm dropped as much as 15.7% to A$32.1, as of 0214 GMT, hitting their record weakest session.
($1 = 1.5389 Australian dollars)
(Reporting by Rajasik Mukherjee; Editing by Alan Barona and Rashmi Aich)
Ramsay Health Care posted a net profit after tax of A$24 million for the year ended June 30.
The decline was attributed to a one-off post-tax charge and poor performance from its European division and British mental health service business.
Shares of Ramsay Health Care dropped as much as 15.7% to A$32.1, marking their weakest session.
Ramsay has hinted at a potential sale of its European arm, Ramsay Santé, and has appointed Goldman Sachs to explore strategic options.
Ramsay's results missed the Visible Alpha consensus estimate of A$70.4 million, indicating a significant shortfall.
Explore more articles in the Finance category
